Article

Preparing of pellets by extrusion/spheronization using different types of equipment and process conditions.

Department of Pharmaceutical Technology, University of Szeged , Szeged , Hungary and.
Drug Development and Industrial Pharmacy (Impact Factor: 1.54). 04/2013; DOI: 10.3109/03639045.2013.783588
Source: PubMed

ABSTRACT Abstract Introduction: The focus of this work was to produce matrix pellets made by extrusion/ spheronization using two types of equipment. The aim was to accomplish the laboratory-scale I process that has been already optimized and accepted with another type of equipment (laboratory-scale II). Methods: A matrix pellet formulation consisting of MCC, Eudragit NE 30D and diclofenac sodium was used in the two types of equipment. Physico-chemical parameters and the dissolution profiles of the pellets in phosphate buffer pH 6.8 were compared. Results: Pellets from both processes were similar in shape and tensile strength. They differed in particle size and dissolution profile. This may be contributed to different spheronization conditions.

1 Bookmark
 · 
241 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Flat die presses are commonly used for the compaction of food, wood, waste, feedstuff, and chemicals. Because of their large capacity, low price, and high production speed, flat die presses represent a promising alternative for conventional extruders used in the pharmaceutical industry. In this work the feasibility of using the flat die press 14-175 for the manufacture of pharmaceutical pellets by extrusion/spheronization was investigated. Pellet formulations containing different model drugs (theophylline, paracetamol, hydrochlorothiazide, or furosemide) and excipients (lactose, mannitol, dicalcium phosphate dihydrate, or starch) with different solubility properties were produced using κ-carrageenan as pelletization aid. Pellets with high and low drug strength were tested. The prepared pellet formulations were assessed in terms of size, size distribution, shape, and release properties. All pellet formulations showed a high yield of the pelletization process and a narrow size distribution. The median aspect ratio was approximately 1.1 indicating acceptable roundness with exception of the pellets produced with high dose of furosemide because of the small-sized needle-shaped active ingredient. The dissolution profiles of the produced formulations showed fast drug release with low standard deviation thus suggesting good batch uniformity. The flat die press is a promising choice for the production of pellets by wet extrusion/spheronization with high formulation robustness.
    Drug Development and Industrial Pharmacy 04/2011; 37(4):456-64. · 1.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study was concerned with the feasibility of formulating ranitidine into pellets with a range of alternative excipients in place of microcrystalline cellulose (MCC). Eight ranitidine formulations employing two or more of the excipients lactose, barium sulfate, glyceryl monostearate, and MCC were processed by extrusion-spheronization, and characterized according to a series of physico-mechanical and dissolution criteria. Formulations containing lactose produced unsatisfactory pellets of wide size distribution and irregular shape, whereas formulations incorporating barium sulfate and glyceryl monostearate with or without MCC resulted in relatively spherical pellets of narrow size distribution and good mechanical properties. Ranitidine release was found to be rapid and virtually complete within 15 min, regardless of the pellet formulation. A direct relationship was observed between the concentration of MCC in the formulation and the properties of the pellets. In general, the higher the concentration of MCC, the rounder, stronger, and less friable the pellets. However, even pellets without MCC were also successfully prepared with a superior size distribution and shape over those with MCC. Overall, these results confirm that ranitidine can be formulated into pellet dosage forms with little or no MCC by the extrusion-spheronization process.
    Pharmaceutical Development and Technology 02/1999; 4(4):499-505. · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objectives of this study were to evaluate the mechanical and thermal properties of films prepared from Eudragit NE 30D/Eudragit L 30D-55 blends and to examine the dissolution behavior of beads coated with the polymer blends up to 120% weight gain. Eudragit NE 30D and L 30D-55 dispersions were blended at 50:50, 67:33, 75:25, and 80:20 ratios. Cast films were evaluated by texture analysis and differential scanning calorimetry. Increasing Eudragit NE 30D concentration increased miscibility, softness, and decreased stiffness of the films. At 80:20 ratio, the polymer blend was completely miscible whereby Eudragit L 30D-55 was molecularly distributed in the mixture. This was confirmed by SEM analysis. The surface morphology of films and beads was evaluated before and after dissolution by scanning electron microscopy. SEM analysis demonstrated that the size of the pores formed after the dissolution of Eudragit L 30D-55 at pH 6.8 was dependent on the miscibility of the Eudragit blend. The implications of this effect were apparent in dissolution studies. For the 75:25 and 80:20 blends, a linear increase in lag time up to 7 h was observed with an increase in coat weight gain from 15 to 120%. At 60% weight gain, the 80:20 blend delayed drug release by approximately 7 h whereas the less miscible 75:25 blend delayed drug release by only 3.5 h. A lag time could therefore be controlled by manipulating both the theoretical weight gain of the beads and the concentration of Eudragit NE 30D in the blend.
    International Journal of Pharmaceutics 07/2008; 357(1-2):219-27. · 3.99 Impact Factor

Full-text

View
180 Downloads
Available from
Jun 5, 2014